APA (7th ed.) Citation

Eminowicz, G., Alexandre, J., Sanchez, L. M., Braicu, I., Madry, R., Taskiran, C., . . . Monk, B. (2025). 1221TiP GOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC). Annals of Oncology, 36, S790. https://doi.org/10.1016/j.annonc.2025.08.1856

Chicago Style (17th ed.) Citation

Eminowicz, G., et al. "1221TiP GOG-3119/ENGOT-en29/TroFuse-033: A Phase III, Randomized Study of Sacituzumab Tirumotecan (sac-TMT) + Pembrolizumab (pembro) Vs Pembro Alone as First-line (1L) Maintenance Therapy for Mismatch Repair-proficient (pMMR) Endometrial Cancer (EC)." Annals of Oncology 36 (2025): S790. https://doi.org/10.1016/j.annonc.2025.08.1856.

MLA (9th ed.) Citation

Eminowicz, G., et al. "1221TiP GOG-3119/ENGOT-en29/TroFuse-033: A Phase III, Randomized Study of Sacituzumab Tirumotecan (sac-TMT) + Pembrolizumab (pembro) Vs Pembro Alone as First-line (1L) Maintenance Therapy for Mismatch Repair-proficient (pMMR) Endometrial Cancer (EC)." Annals of Oncology, vol. 36, 2025, p. S790, https://doi.org/10.1016/j.annonc.2025.08.1856.